Rosiglitazone is no longer commonly used in diabetes treatment, due in part to concerns that it increased risk of cardiac events [a claim the FDA later disputed (55)], and thus further research with other insulin sensitizers may be warranted. The gene discussed is INS; the disease is diabetes mellitus.